Psilocybin

Primary targets and binding profile: Psilocybin is pharmacologically inert until conversion to psilocin. Psilocin is a serotonergic psychedelic whose acute subjective effects depend strongly on 5-HT2A receptor agonism; human and translational studies further implicate 5-HT2C and 5-HT1A signalling in shaping acute effects and downstream physiological responses. In receptor binding work, psilocin shows broadly similar submicromolar affinities across 5-HT2A, 5-HT2C, and 5-HT1A (for example, reported Ki ranges around 120–173 nM for 5-HT2A; 79–311 nM for 5-HT2C; and ~146–152 nM for 5-HT1A), supporting a multi-receptor serotonergic profile rather than an exclusively 5-HT2A-selective mechanism.

Metabolism and active metabolites: In humans, psilocybin is rapidly dephosphorylated to psilocin via alkaline phosphatase and related phosphatases/esterases; psilocin is then cleared mainly through glucuronidation (psilocin-O-glucuronide is a major circulating and urinary metabolite) with additional oxidative pathways (including monoamine oxidase-mediated routes leading to metabolites such as 4-hydroxyindole-3-acetic acid). Contemporary pharmacokinetic reviews highlight that plasma concentrations of conjugated psilocin can exceed unconjugated psilocin, and that elimination is largely complete within a day despite wide inter-individual variability in exposure.

Onset, peak, duration, and routes: In supervised clinical use, psilocybin is typically administered orally (capsule or similar), with onset commonly within ~20–40 minutes, peak subjective effects at ~60–90 minutes, and an active duration around 4–6 hours; some clinical programmes describe dosing-day psychedelic effects lasting roughly 6–8 hours when psychological support and recovery time are included. Intravenous administration produces a faster peak and can shorten the experiential window relative to oral dosing by bypassing absorption and first-pass metabolism; however, IV psilocybin remains primarily a research route rather than a standard therapeutic format.

Dose–response characteristics in trials: Modern depression trials have converged on fixed-dose regimens broadly comparable to 25 mg oral psilocybin (or equivalent), with evidence of dose separation in TRD development programmes. In the COMPASS Phase IIb dose-finding trial, participants were randomised to 1 mg, 10 mg, or 25 mg; the 25 mg condition showed the clearest symptomatic improvement versus 1 mg at early follow-up. The Phase III TRD programme focused on 25 mg dosing (single dose versus placebo in COMP005; and one or two 25 mg doses versus a 1 mg control in COMP006), reflecting a strategic shift towards effect confirmation and durability optimisation. [1]Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD (COMP005)

Neuroimaging and biomarkers: Mechanistic studies suggest that psilocybin can acutely and subacutely alter large-scale brain network dynamics. In an early fMRI study in TRD, Carhart-Harris and colleagues reported post-treatment decreases in cerebral blood flow in temporal regions including the amygdala (correlating with symptom improvement) alongside changes in default mode network connectivity. PET data indicate that intensity of the acute psychedelic experience correlates with 5-HT2A receptor occupancy and plasma psilocin exposure, linking central target engagement to phenomenology rather than assuming it.

Neuroplasticity mechanisms remain a central hypothesis but are still being translated from preclinical to clinical evidence. In rodents, a single dose has been shown to induce rapid increases in dendritic spine density and size in frontal cortex (on the order of ~10%), with persistence for weeks, supporting a plausible biological substrate for enduring behavioural change after brief exposure. In humans, peripheral biomarkers such as BDNF are under active investigation, but recent syntheses caution that peripheral BDNF changes are inconsistent across studies and may not reliably index brain plasticity in a clinically actionable way.

Common adverse events in clinical trials: Across monitored studies, therapeutic-dose psilocybin is most consistently associated with transient headache, nausea, fatigue, dizziness, and acute anxiety, alongside short-lived increases in blood pressure; systematic reviews and meta-analyses conclude that these effects are usually self-limiting and resolve within 48 hours under clinical supervision, but emphasise that more rigorous and standardised adverse-event measurement is needed as trials scale and broaden eligibility.

Serious adverse events and psychiatric vulnerability: Serious adverse events (SAEs) are uncommon overall in contemporary psychedelic trials, but they do occur, and appear concentrated in participants with pre-existing neuropsychiatric disorders rather than healthy volunteer samples. Suicidal ideation and intentional self-injury have been reported in TRD populations across dose groups in psilocybin trials, requiring careful interpretation because baseline risk is high in TRD cohorts; nonetheless, these events materially shape risk management and regulatory scrutiny. COMPASS Pathways’ Phase III press release stated that no serious unexpected suspected adverse reactions occurred, while still reporting adverse events such as headache and nausea as common, and highlighting ongoing monitoring of suicidality and related events.

Cardiovascular and other organ-system considerations: Psilocybin does not appear to carry a prominent direct organ-toxicity signal in controlled single- or few-dose studies, but transient autonomic effects (blood pressure and heart rate increases) are sufficiently consistent that protocols usually exclude uncontrolled hypertension and significant cardiovascular instability and require vital-sign monitoring during dosing and recovery. Contemporary adverse-event reviews note that medical intervention is rarely needed, but can be required in isolated cases (for example for sustained anxiety, hypertension, or emergent psychiatric distress), reinforcing the clinical importance of skilled session monitoring rather than assuming benignity.

Abuse potential and dependence liability: Psilocybin’s dependence liability is generally considered low relative to reinforcing substances such as opioids, stimulants, or alcohol, with rapid tolerance and minimal evidence of a classic withdrawal syndrome. A structured “8-factor” analysis aligned to the US Controlled Substances Act has argued that medically administered psilocybin would likely warrant rescheduling if approved, but that appropriate controls would still be needed due to acute impairment, diversion risk, and the need for supervised administration.

Contraindications and drug–drug interactions: Most modern protocols exclude patients with current psychotic disorders and typically screen out bipolar I disorder or strong bipolar-spectrum risk because case-report syntheses suggest potential for mania activation in vulnerable individuals. Concomitant medication management remains an evolving area: many trials historically required tapering serotonergic antidepressants to minimise confounding and potential blunting of psilocybin effects, but scoping reviews suggest that classic psychedelics combined with conventional antidepressants are often tolerated without robust evidence of serotonin syndrome, while acknowledging that available evidence is limited and heterogeneous. In contrast, coadministration with lithium is a clearly elevated risk scenario: analyses of naturalistic reports have associated lithium-plus-psychedelic use with a substantial seizure signal, and this risk is taken seriously in contemporary clinical screening.

Risk management safeguards and likely post-approval controls: Contemporary psilocybin protocols operationalise safety through structured “set and setting” safeguards—screening, preparation sessions, continuous monitoring during dosing, and integration support afterwards—because important harms are psychological and behavioural rather than toxicological. If a regulated psilocybin medicine receives marketing authorisation in the US, a restricted distribution and supervised-administration model analogous in spirit (though not identical in content) to existing REMS programmes for psychoactive in-clinic treatments is plausible, given established FDA precedent for medicines requiring on-site dosing and post-dose monitoring for dissociation/sedation (as with esketamine).

Psilocybin is one of the most clinically mature classic psychedelics, with the current late-stage depression story centered on COMP360 for treatment-resistant depression and adjacent work in major depressive disorder. The practical path is treatment-resistant depression first, then the broader major depressive disorder evidence map, because those pages show how the compound-level story changes by indication.

Compass reported a positive second Phase 3 COMP360 trial in February 2026, then said in April 2026 that FDA granted a rolling-review request for the NDA and awarded a Commissioner's National Priority Voucher. [1]Compass FDA rolling review release [2]Compass COMP360 Phase 3 release In July 2026 Compass added 26-week (six-month) data from the second Phase 3 trial (COMP006, nearly 600 patients), reporting that 39% of the 25 mg arm reached a clinically meaningful MADRS reduction (at least 25%) by week 6 and maintained a durable response through week 26, and confirmed that the rolling NDA submission was underway. [3]Compass Pathways That is a regulatory-process signal, not an FDA approval, so psilocybin is late-stage and closely watched rather than available medicine.

Evidence comparison works best as a route into the broader evidence atlas. Treatment-resistant depression supplies the disease context, while the compound-by-topic research view covers dose patterns, adverse events, and trial-paper coverage.

Indications with the strongest evidence: TRD now sits at the top of the evidence hierarchy because it has replicated Phase III trial success in a consistent dosing framework (25 mg COMP360 with psychological support) and a clearly defined regulatory path. If subsequent full datasets confirm clinically meaningful durability and acceptable safety in a high-risk population, TRD is positioned to become the first mainstream medical indication for a psilocybin-based intervention in major jurisdictions.

MDD is the next-most mature indication: multiple Phase II datasets (including multisite randomised evidence with 25 mg dosing versus active placebo) support efficacy and tolerability in selected patients, and Phase III programmes are active (notably Usona’s uAspire). [1]Psilocybin for Major Depressive Disorder (MDD) (uAspire) The key near-term clinical questions are not simply symptom reduction but durability, relapse prevention, and how psilocybin-assisted interventions compare against best-available pharmacotherapy and psychotherapy in broader, more comorbid real-world populations.

Oncology-related distress remains compelling but methodologically complex: the effect sizes in the 2016 RCTs were large, and the conceptual fit with palliative psychiatry is strong, but earlier crossover designs and the difficulty of long-term blinding make it challenging to specify optimal dosing frequency, patient selection, and service structure. Larger pragmatic trials and real-world compassionate-use data (where permitted) are likely to clarify clinical value and boundaries of indication.

Addiction profiles represent a high-opportunity, high-complexity frontier. Alcohol use disorder has the most robust randomised evidence so far, with meaningful reductions in heavy drinking metrics over many months; tobacco cessation signals remain unusually strong for a brief intervention, but require confirmatory trials with rigorous comparators and scalable delivery models. Opioid, stimulant, and behavioural addictions are increasingly targeted, but development is constrained by comorbidity, safety screening, and the need to integrate pharmacotherapy with structured behaviour-change protocols.

What next-generation trials are likely to test: Several design tensions are now central. First, medication management: evidence is emerging on whether patients must discontinue SSRIs/SNRIs, with scoping reviews suggesting tolerability but potential blunting, and dedicated trials explicitly studying SSRI interactions. Second, dosing frequency: Phase III TRD programmes are already testing one versus two sessions to optimise durability, and real-world compassionate use may generate further insights while remaining tightly limited. Third, personalisation: baseline neuroimaging/connectivity and other predictors are being evaluated to identify who benefits most and who may be harmed, which is essential for both clinical safety and payer acceptability.

International control baseline: Psilocybin is controlled internationally under the UN Convention on Psychotropic Substances (1971), which established an international system for regulating listed psychotropic substances and strongly shaped national prohibitions and research licensing regimes. This treaty framework remains a foundational constraint even as medical exceptions expand.

United States: At the federal level, psilocybin remains a Schedule I controlled substance under the Controlled Substances Act, meaning lawful possession and supply are restricted to federally authorised research contexts. In parallel, state and local reforms have created divergent access environments: Oregon operates a regulated psilocybin services programme, and Colorado has implemented a regulated access model for psilocybin in licensed healing centres, even while federal Schedule I status continues to complicate banking, interstate commerce, and conventional medical integration.

United Kingdom: Psilocybin is controlled as a Class A drug under the Misuse of Drugs Act 1971 and is placed in Schedule 1 under the Misuse of Drugs Regulations 2001, restricting non-research possession and imposing stringent licensing for scientific and medical work. Parliamentary answers as recently as 2022 reaffirmed that the UK Government had no plans to reassess classification at that time, even amid rising clinical research.

European Union and Germany: Across EU Member States, psilocybin is generally controlled, and medical access typically occurs only within clinical trials. A significant exception pathway now exists in Germany: the Federal Institute for Drugs and Medical Devices (BfArM) approved a Compassionate Use Programme for psilocybin in TRD (effective July 2025), delivered through the Central Institute of Mental Health (ZI Mannheim/CIMH) and OVID Clinic Berlin under the leadership of Gerhard Gründer and colleagues. This is explicitly framed as time-limited and not a substitute for marketing authorisation, but it represents the most concrete EU example of controlled pre-approval access.

Australia and Canada: Australia rescheduled psilocybine preparations to allow prescribing by specifically authorised psychiatrists for TRD from 1 July 2023 (while still lacking a TGA-approved psilocybin medicine), creating a highly controlled clinical-access pathway outside trials. Canada maintains federal control of psilocybin but has expanded physician access routes via amendments to the Special Access Program for restricted drugs, alongside case-by-case exemptions in tightly defined circumstances.

Plausible approval pathway and timelines: In the US, a realistic pathway is an FDA New Drug Application (NDA) for a manufactured psilocybin product with an associated delivery model; if approved, rescheduling under the Controlled Substances Act would be required for lawful prescription use, and risk-management controls would likely include supervised administration and post-dose monitoring given acute impairment risks. COMPASS Pathways has since advanced along that path: in April 2026 the FDA granted a rolling-review request for the COMP360 NDA in TRD and selected it for the Commissioner's National Priority Voucher programme, which carries a shortened one-to-two-month review window once the application is formally filed. The rolling submission is now underway with final completion on track for Q4 2026, and the company anticipates a potential US launch in the first half of 2027, subject to FDA approval.

Market structure: Psilocybin commercialisation is structurally different from conventional chronic psychopharmacology because the intervention is typically delivered as a supervised session embedded in a structured psychological support model. This creates a two-sided scale problem: drug manufacturing is comparatively straightforward, but capacity is constrained by trained staff, physical space, and multi-hour dosing-day logistics—factors that directly influence pricing, payer adoption, and time-to-access.

COMPASS Pathways: COMPASS’ COMP360 is the most advanced commercial programme, supported by replicated Phase III data in TRD and an explicitly stated plan to pursue NDA submission in Q4 2026. COMPASS has also built an IP strategy around crystalline psilocybin forms and TRD treatment methods (including US patents covering crystalline psilocybin used in COMP360), signalling an intent to protect a branded psilocybin product-plus-protocol rather than a commodity API. Commercially, this supports payer-facing differentiation but also increases the likelihood of ongoing patent scrutiny and competitive challenges.

Usona Institute: Usona represents a distinct “open science” and public-benefit approach. It has launched a Phase III MDD study (uAspire) and has historically emphasised broad research enablement rather than a conventional patent moat around psilocybin itself. [1]Psilocybin for Major Depressive Disorder (MDD) (uAspire) If uAspire succeeds, it could increase competitive pressure on proprietary psilocybin formulations by demonstrating that clinical value is not limited to a single commercial sponsor, while still leaving ample room for proprietary delivery, training, and service models.

Second-generation and analogue strategies: A major commercial thesis is “same benefit, lower burden”. Cybin’s CYB003 (a deuterated psilocin/psilocybin analogue) is explicitly positioned to shorten duration of action, reduce inter-subject variability, and improve clinical scalability; company materials report durable antidepressant signals in small Phase II cohorts and describe an initiated Phase III programme, with Breakthrough Therapy Designation reported for MDD. These claims are directionally coherent with the broader industry’s drive towards shorter sessions and more predictable kinetics, but they remain dependent on confirmatory Phase III outcomes and on whether “shorter and more predictable” translates into better real-world effectiveness and safety.

Natural-product and supply-chain approaches: Filament Health is advancing a botanical psilocybin candidate (PEX010) and has partnered with academic centres (including UCL) for Phase II research programmes. Filament is also supplying material to Germany’s Compassionate Use Programme in TRD, which could generate rare pre-approval real-world data under strict controls, although scale is intentionally limited and demand is expected to exceed capacity.

Timing and probability of first approval: Based on available public information as of February 2026, the most plausible “first approval” scenario for a psilocybin-based medicine in a major regulator-led market is a TRD indication in the US following completion of COMPASS’ Phase III programme and subsequent NDA review, with compulsory controlled-substance rescheduling and likely restricted distribution/supervised administration requirements. While timelines are uncertain, COMPASS’ stated plan for NDA submission in Q4 2026 implies that any US marketing authorisation would be expected after that point rather than before it.

Within-class comparison (classic psychedelics): Psilocybin sits between DMT and LSD on a session-duration and service-burden spectrum. In supervised oral use, psilocybin’s acute effects generally unfold over hours, enabling a full dosing-day therapeutic protocol that is intensive but feasible in outpatient-style specialist settings. LSD’s longer duration increases logistical and staffing demands, which can reduce clinical tractability despite mechanistic similarities as a 5-HT2A-mediated psychedelic. DMT’s much shorter action can, in principle, reduce time burden, but its intensity and the need for more tightly controlled delivery (often via inhalation or intravenous routes in research settings) introduce different operational and safety-management challenges.

Comparison with dissociative rapid-acting antidepressants: Esketamine is an instructive comparator because it is already approved for TRD and is delivered under a strict REMS requiring supervised administration and at least 2 hours of monitoring after each treatment session. This demonstrates that regulators and payers will accept a clinic-anchored drug model when benefit–risk is acceptable and protocols are enforceable. Relative to esketamine, psilocybin aims to reduce the frequency of clinic visits (often one or two supervised sessions rather than frequent dosing), but each psilocybin session is longer and more psychotherapy-dependent, shifting burden from dosing frequency to session intensity and specialised staffing.

Safety, therapeutic index, and scalability: Psilocybin’s physical toxicity and dependence liability are generally low in controlled settings, but its clinical risk profile is disproportionately psychiatric (acute anxiety, destabilisation in vulnerable individuals, post-dose crises in high-risk depression cohorts), making screening and monitoring central to safety. For ketamine/esketamine, dissociation and abuse/misuse concerns are more prominent, reflected in controlled distribution and monitoring requirements. Commercially, psilocybin’s competitive advantage is the possibility of durable benefit after few administrations, while its principal disadvantage is the labour-intensive nature of delivery. This is why “next-generation” tryptamine analogues (for example deuterated candidates) are strategically positioned to compete not only on efficacy but on operational fit, by shortening duration and reducing variability.